More Information on 'Diagnoplex SA'

About Diagnoplex SA
We are a dedicated and multi-disciplinary team focused on bringing true innovation to personalized cancer care. With our unique and proprietary molecular platform and state-of-the-art biostatistical tools, we develop blood-based cancer diagnostic tests. Our initial focus is on systematic screening for colorectal cancer. This is an area of increasingly urgent and unmet medical need as a result of an ageing population and representing an estimated market opportunity of $3.5 billion. Diagnoplex’s lead product, Colox®, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox® has been designed to detect early and advanced disease stages with outstanding results and reliability. Colox® leverages the information from nucleic acids carried by peripheral blood mononuclear cells (PBMCs). PBMCs are instrumental for tumor-host interactions, the so-called “host response”, and are involved at the earliest stages of tumor formation. Our ability to screen for the host response enables us to detect colorectal cancer risk at the earliest and even pre-cancerous stages. In a pilot validation study, Colox® has been shown to be equivalent to currently recommended non-invasive procedures. Because Colox pairs convenience with higher accuracy, colorectal cancer can be identified earlier and thereby improving the odds of survival. Colox® will facilitate compliance with colorectal cancer primary screening guidelines for people ‘at risk’, i.e. those over 50 years of age, without the need for bowel preparation, sedation or risk of colon perforation.